IPSEN S A/S (OTCMKTS:IPSEY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $29.00 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 7.01% from the stock’s previous close.
According to Zacks, “Ipsen S.A. is a pharmaceutical company. It provide drugs for urology, oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology and cardiovascular. Ipsen S.A. is headquartered in Boulogne-Billancourt, France. “
Several other research analysts also recently issued reports on IPSEY. Societe Generale downgraded shares of IPSEN S A/S from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Morgan Stanley reiterated an “overweight” rating on shares of IPSEN S A/S in a research note on Tuesday, September 1st. ValuEngine cut shares of IPSEN S A/S from a “hold” rating to a “sell” rating in a report on Monday, August 3rd. Bank of America raised shares of IPSEN S A/S from a “neutral” rating to a “buy” rating in a report on Monday, June 1st. Finally, UBS Group reissued a “buy” rating on shares of IPSEN S A/S in a report on Tuesday, August 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. IPSEN S A/S currently has a consensus rating of “Hold” and an average price target of $29.00.
IPSEN S A/S Company Profile
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
See Also: What is the CAC 40 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.